P ercutaneous coronary intervention with stent implantation is the standard of care in patients with ST-segmentelevation myocardial infarction (STEMI). 1 Patients treated with first-generation drug-eluting stents (DES) had lower rate of target lesion revascularization than patients treated with bare-metal stents (BMS) at 5 years. 2 However, this reduction was only observed during the first year after stent implantation. The analysis of the subsequent years (from 1-5 years) showed higher rate of target lesion revascularization in the group treated with first-generation DES than in the group treated with BMS. This was caused by a higher incidence of very-late stent thrombosis (ST) in the group treated with firstgeneration DES. 2 Moreover, it is also remarkable that the incidence of late ST has no attenuation neither with DES nor with BMS at very long-term follow-up (>5 years). 3, 4 Second-generation DES, such as everolimus-eluting stent (EES), have shown an important decrease of the very-late ST rate (0.3-0.6% per year) as compared with first-generation Background-The main causes of late (>1 month) stent thrombosis (ST) are stent uncoverage, malapposition, and neoatherosclerosis. First-generation drug-eluting stents were associated with higher rate of late ST compared with bare-metal stents (BMS), especially in patients with ST-segment-elevation myocardial infarction. Second-generation everolimus-eluting stents (EES) have shown similar rate of late ST than BMS. The aims of the study are to compare the ratio of uncovered to total struts per cross-section ≥30% and other optical coherence tomographic findings associated with ST between EES and BMS in patients with ST-segment-elevation myocardial infarction at 5 years.
The RE-EXAMINATION Study DES (1.6-2.4% per year). 3, 5 In patients with STEMI, EES have been shown more effective than BMS at 5-year followup. In the EXAMINATION study (A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction), the composite device-oriented end point of cardiac death, target vessel myocardial infarction, and target lesion revascularization was observed in 11.9% versus 15.5% of patients treated with EES and BMS, respectively (P=0.04). 5 However, the lower event rate observed with EES, as compared with BMS, was mainly observed during the first year after stent implantation; the analysis of the subsequent years after the first year showed no differences between both devices. 5 According to pathology studies, lack of strut coverage is the most important predictor of late ST (>1 year). 6 Stents with a ratio of uncovered to total stent struts per cross-section (RUTSS) ≥30% were associated with higher risk of late ST. 6 Stent malapposition and ruptured neoatherosclerotic plaques have been also defined as other important predictors of late ST according to optical coherence tomographic (OCT) studies. 7, 8 It is also remarkable that stents implanted in the setting of STEMI had larger number of uncovered and malapposed struts and had higher rate of late ST than stents implanted in other clinical settings. [9] [10] [11] The main objective of the study is to compare the number of lesions with at least one cross-section with RUTSS ≥30% between EES and BMS in STEMI patients, as assessed by OCT, at 5-year follow-up. This study also aims to compare other OCT findings associated with the occurrence of late ST such as the presence of stent malapposition and neoatherosclerotic plaques between EES and BMS.
Methods

Population and Procedure Characteristics
The EXAMINATION study was a randomized, controlled, allcomers, multicenter trial (NCT00828087). From 2008 to 2010, the EXAMINATION trial recruited 1504 patients with STEMI. All patients were randomized 1:1 to one of the 2 treatment arms: EES (Xience V stent) versus BMS (Multilink-Vision stent). Both stents have the same cobalt-chromium platform with strut thickness of 81 μm. The design and results of the EXAMINATION study have been reported previously. 5 For the purpose of the present study, all consecutive event-free patients included in the EXAMINATION study from September 2009 to January 2010 in 2 participating institutions were screened to participate in the RE-EXAMINATION study at 5 years of the stent implantation. The exclusion criteria of the RE-EXAMINATION study included patients experiencing death, target vessel myocardial infarction, or target lesion revascularization during the 5 years after stent implantation. Patients with creatinine clearance <45 mL•min −1 •m −2 , known hypersensibility, allergic reaction to contrast, chronic oral anticoagulation, left ventricular ejection fraction ≤30%, platelet count <75 000/mm 3 or >700 000/mm 3 , life-threatening disease, or inability to provide informed consent were also excluded.
All suitable patients were contacted by phone and were invited to participate in the study. Patients accepting the protocol were cited to the outpatient clinic and signed written informed consent. All patients included in the RE-EXAMINATION study underwent physical examination, ECG, and blood test before coronary angiography. Follow-up coronary angiography was performed according to standard procedures at the 2 participating institutions. The Material section in the Data Supplement summarizes the scheduled follow-up procedure.
This study was approved by the local ethics committee of all participating institutions and was done in accord with the Declaration of Helsinki. Written informed consent was obtained from all patients.
Angiographic Analysis
Angiographic analysis was performed by a dedicated Core-lab (BARCICORE-lab, Barcelona, Spain) using specific software for quantitative coronary angiography analysis (CASS; Pie Medical, Maastricht, the Netherlands). Two blinded analysts were requested to match the target coronary segment at index procedure and follow-up. After adequate calibration, the in-stent region (defined by the segment between the 2 stent edges) and the in-segment region (defined by the segment between the 5 mm proximal and 5 mm distal to the stent edges) were analyzed. The interpolate-reference vessel diameter; maximal, mean, and minimal lumen diameter; and diameter stenosis were measured according to the core laboratory standard procedures. 12 
OCT Analysis
OCT analysis was also performed by a dedicated Core-lab (BARCICORE-laboratory) using specific software for analysis (LightLab Imaging, Westford, MA). Two blinded analysts were requested to assess the following qualitative OCT findings in the entire OCT pullback (0.2 mm intervals): the observation of cross-sections with RUTSS ≥30% in 1 and 3 consecutive OCT cross-sections, the neointima pattern at the cross-section with largest neointima area, the presence of signal-rich bands, and finally the observation of neoatherosclerotic plaques. Figure 1 shows the assessment of the OCT qualitative findings of the present study. The Material section in the Data Supplement shows the definition and the core laboratory reproducibility of those OCT findings.
Quantitative analysis was performed at 1 mm intervals within the stent segment and 5 mm proximal and distal to the stent edges. The OCT software drew the lumen area automatically. Stent area was drawn at the adluminal site of the metallic struts. The neointimal area
WHAT IS KNOWN
• Patients with ST-segment-elevation myocardial infarction treated with stent implantation are at high risk of very-late stent thrombosis. Secondgeneration drug-eluting stents has reduced the risk of very-late stent thrombosis as compared with first-generation drug-eluting stents.
• Lack of strut coverage, malapposition, and neoatherosclerosis are the main findings observed in cases with very-late stent thrombosis. However, little data exist on the prevalence of these findings in event-free patients 5 years after stent implantation in the setting of ST-segment-elevation myocardial infarction.
WHAT THE STUDY ADDS
• As assessed by optical coherence tomography, uncovered struts, stent malapposition, and neoatherosclerosis are common in ST-segment-elevation myocardial infarction patients treated with either bare-metal stents or second-generation drug-eluting stents, which have remained uneventful 5 years after the stent implantation.
• Although watchful follow-up of these cases is warranted, the low event rate at long-term follow-up suggests that these findings contribute to very-late stent thrombosis in a small percentage of cases.
was calculated as the difference between the stent and luminal areas. The neointimal thickness was automatically calculated from the center of the adluminal side of the strut to the lumen contour with the thickness ruler tool. Assessment of strut coverage and apposition is also shown in the Material section in the Data Supplement.
Statistical Analysis
The study was designed to assess inferiority of BMS versus EES in the number of lesions with RUTSS ≥30% at 5 years. The sample size calculation is described in the Material section in the Data Supplement.
Categorical variables were presented as counts and percentages, and continuous variables as means±1 SD. Quantitative OCT data were presented as means (95% confidence interval). Comparisons of continuous variables were estimated using Student t test when sample size was large and Mann-Whitney test when small and data possibly skewed. Test and comparisons of categorical variables were estimated with the χ 2 test. Strut-level analysis was performed taking into account the clustering nature of the OCT data with generalized estimating equations. All struts (>13 000) were classified into the following types: apposed and covered, apposed and uncovered, malapposed and covered, and malapposed and uncovered. Each strut type was introduced in the generalized estimating equations as dependent variable using the binary logistic model. Each model was performed introducing the stent type as covariate and the patient identification as subject variable (62 patients). A 2-sided P value ≤0.05 was considered statistically significant. The Mantel-Cox method was used to calculate rate ratios, 95% confidence interval for comparisons of clinical outcomes between groups, and the log-rank test to calculate corresponding P values. Reproducibility analysis of qualitative OCT findings was performed with the Cohen κ test for concordance and is shown in Table I in the Data Supplement. Statistical analysis was performed with the SPSS software, version 20.0 (SPSS, Chicago, IL).
Results
Population
About 40% of eligible subjects had OCT imaging after 5 years. Of 169 eligible, only 108 agreed to participate. Of these 108, 64 completed follow-up and 44 subjects dropped out during follow-up, mostly for medically related reasons. Figure 2 indicates that dropout patterns were similar in the 2 study arms. Finally, the RE-EXAMINATION study included 32 patients treated with EES and 32 patients treated with BMS. The baseline clinical and angiographic characteristics of all patients screened to participate in the study are shown in Table II in the Data Supplement. The clinical end points of all consecutive patients screened to participate in the present study are shown in Table III in the Data Supplement. Figure 3 shows the Kaplan-Meier curves of the main outcomes observed during the 5 years. In summary, patients treated with EES presented with similar patient-and device-oriented end points as BMS.
However, patients treated with EES presented with lower rate of target vessel myocardial infarction and target vessel revascularization than those treated with BMS. Table 1 shows the clinical characteristics of patients included in the RE-EXAMINATION study at the time of the follow-up angiography (5 years). There were no statistically significant differences between patients treated with EES and BMS. Table 2 shows the baseline and 5-year angiographic characteristics of patients included in the study. There were no statistically significant differences between the 2 study device groups. The baseline and 5-year clinical characteristics of patients included in the RE-EXAMINATION study are shown in Table IV in the Data Supplement. 
Quantitative Angiographic Results
All 64 patients of the study were suitable for quantitative coronary angiographic analysis. Table 2 shows the quantitative coronary angiographic analysis at baseline and at 5 years according to the treatment arm. Baseline angiographic and procedural characteristics were similar between groups. At 5 years, patients treated with EES presented a trend toward of larger minimal lumen diameter (2.19±0.49 versus 1.95±0.47 mm; P=0.06) and statistically significant lower diameter stenosis (13.63±21.81% versus 26.77±14.28%; P<0.01) and lower late lumen loss (0.26±0.31 versus 0.60±0.34 mm; P<0.01) than those treated with BMS, respectively.
Qualitative OCT Results
A total of 62 patients were suitable for OCT analysis. Two experienced analysts visually reviewed 8439 OCT cross-sections; 218 out of them in 6 patients were excluded because of poor quality (mainly residual blood) and ostial location of the stents (with intubation of the catheter into the stent). Table 3 shows the qualitative OCT findings at 5 years according to the treatment arm. Lesions with at least 1 cross-section with RUTSS ≥30% were observed in 35.5% of patients treated with EES versus 9.7% with BMS (P=0.02). Uncovered and nonapposed struts were also observed in more lesions treated with EES (38.7%) versus BMS (16.1%; P=0.05). Figure 4 shows the spatial distribution of the 4 strut types (covered and apposed, covered and malapposed, uncovered and apposed, and uncovered and malapposed) in all study devices. There were no differences in the neointimal pattern at the cross-section with large neointima between groups. The most frequent pattern observed in both groups (>80%) was the homogeneous pattern. Neoatherosclerotic plaques were observed in 16.1% versus 25.8%, respectively (P=0.35). Signal-rich bands were observed in 19.4% versus 48.4%, respectively (P=0.02). Patients with potential OCT characteristics Figure 5 shows the main OCT findings of the study. Table 4 shows the quantitative OCT findings at 5 years according to the treatment arm. EES presented with larger number of uncovered struts (4.1%) than that with BMS (1.0%) according to the total number of struts (P<0.01). EES also presented with larger number of malapposed struts (1.2%) than that with BMS (0.3%; P=0.02). Luminal volume was similar between both groups (141.6 versus 126.9 mm 3 ; P=0.39). Stent volume was also similar between both stents (166.6 versus 173.6 mm 3 ; P=0.74). However, neointimal volume was statistically lower with EES (24.1 mm 3 ) than that with BMS (46.5 mm 3 ; P<0.01). The maximal neointimal area obstruction was also lower with EES (31.7%) than that with BMS (47.0%; P<0.01).
Quantitative OCT Results
Discussion
The main findings of the present study are: (1) five-year eventfree patients treated with EES in the setting of STEMI have larger number of lesions with uncovered and malapposed struts than patients treated with BMS and (2) BMS presented with a numerically higher incidence of neoatherosclerotic plaques and with statistically significant larger amount of signal-rich bands than that with EES. Current revascularization guidelines recommend the use of second-generation DES (ie, EES) compared with BMS in patients undergoing primary percutaneous coronary intervention. 13 The 5-year results of the EXAMINATION study reinforce this recommendation because of the better outcomes observed with EES compared with BMS. The annual rate of very-late ST observed with EES (0.3% per year) and with BMS (0.15% per year) is the lowest ever reported in STEMI patients. 5 Nevertheless, the rate of very-late ST observed with EES can be still remarkable in young STEMI patients if there is no attenuation of the incidence at very long-term follow-up.
Stent implantation in STEMI patients has been shown to be one of the major predictors of early and late ST. 9 Several mechanisms have been attributed to the larger risk of ST in patients with STEMI. First, the healing process of culprit STEMI plaques (mostly ruptured thin-cap fibroatheromas) is delayed and exhibits less neointimal growth and greater inflammation, fibrin deposition, and uncovered struts than stents implanted in nonculprit sites within the same stent. Stents implanted in plaques responsible for stable angina also showed greater neointimal growth than stents implanted in the setting of STEMI. 11, 14 Second, stent size in patients with STEMI tends to be underestimated because of the presence of thrombus and vessel spasm with subsequent acute stent malapposition. The acute strut malapposition hampers the healing process in the first weeks after stent implantation, and these stents are at larger risk of malapposition and lack of neointimal coverage at follow-up than apposed struts immediately after stent implantation. 11, 15 The analysis of the culprit plaque characteristics behind the struts was feasible in >80% of patients. According to the OCT images at 5 years, >60% of observed culprit plaques located behind the struts had some degree of calcification. There were no differences between the healing parameters between calcified and noncalcified plaques.
According to pathology case-control studies, the most important cause of late ST is lack of strut coverage. Specifically, the observation of uncovered struts in consecutive cross-sections. 6, 14 OCT studies have observed >5% of uncovered struts in >65% of patients with drug-eluting very-late ST. 6, 16 Fiveyear OCT imaging of event-free patients treated with sirolimus-or paclitaxel-eluting stents showed that the percentage of patients with uncovered struts >5% was 10.7% with sirolimusand 7.2% with paclitaxel-eluting stents. 17 In the present study, including only STEMI patients, 32.3% and 6.5% of patients treated with EES and BMS had >5% of uncovered struts.
However, OCT studies in patients with late ST have shown malapposition and ruptured neoatherosclerotic plaques as the main causes of the ST. 7, 8 In those studies, the presence of malapposition (32% to 35%) and ruptured neoatherosclerotic plaques (28%) was more frequent than isolated uncovered struts (8% to 12%) in patients with late ST. 7, 8 According to previous publications, very-late ST of BMS are probably caused by ruptured thin-cap neoatherosclerotic plaques. 18 On the contrary, very-late ST of DES are probably caused by malapposition and lack of strut coverage. 18 The observation of neoatherosclerotic plaques in event-free patients have been reported in 4.9% of patients treated with sirolimus DES and 25.5% of patients treated with paclitaxel DES, at 5 year. 19 The present study observed 16.1% of neoatherosclerotic plaques in patients treated with EES and 25.8% in patients treated with BMS. However, it is remarkable that 58% of EES and 20% of BMS did not have 30% of maximal neointimal area stenosis as assessed by OCT. It is plausible that the probability to develop neoatherosclerosis may be related with the amount of the underlying neointima. Table V Therefore, the excellent clinical results observed in the allcomers EXAMINATION study at 5 years (<16% of deviceoriented end point and <3.5% of definite/probable ST with both stents) are probably caused by the low percentage of patients with malapposition and neoatherosclerosis at 5 years. In the present study, only 3.2% of patients had >5% of malapposed struts and only 21.0% of patients had neoatherosclerotic plaques. Although EES presented with a remarkable percentage of patients with uncovered struts, the clinical relevance of this observation should be under-rated according to the excellent clinical results of the EXAMINATION study. It has been shown that the acrylic and fluoro permanent polymers of the EES cause less inflammatory reaction to the vessel wall than other polymers. 20 The everolimus drug is completely eluted 4 months after stent implantation. Then, the stent behaves as a metallic stent but coated with the permanent polymer. It is possible that the thrombogenicity of the biocompatible permanent polymer may be lower than that observed with uncovered bare metallic struts, even when the strut is uncovered.
Limitations
The present study has several limitations. First, the high proportion of subjects who declined participation or who dropped out before completing follow-up indicates that our results may be biased. Nevertheless, the results suggest that there are medically important differences. Hopefully, future studies will uncover physiological differences that explain these differences. Second, there are automatic methods capable to discern between stent strut coverage with excellent correlation with pathological samples. However, the correlation of these programs with manual measurements is good, and the reproducibility reported in this study shows moderate-to-excellent agreement. Finally, there is no OCT study exploring the correlation of the qualitative OCT findings (ie, RUTSS, malapposition, and neoatherosclerosis) with cardiac outcomes. The clinical relevance of these OCT observations warrant long-term follow-up of patients included in the OCT study and probably larger number All P values were estimated with Student t test. BMS indicates bare-metal stent; CI, confidence interval; EES, everolimus-eluting stent; and OCT, optical coherence tomographic.
*P values were estimated with generalized estimating equations. †Incomplete apposition distance from the abluminal strut border to the lumen wall. The RE-EXAMINATION Study of patients than the present study. Therefore, all conclusions driven by the OCT observations must be taken with caution and are only hypothesis generating. Moreover, it is uncertain whether new neoatherosclerotic plaques can emerge beyond 5 years of the stent implantation, and this propitiate unexpected cases of ST according to the OCT images at 5 years.
Conclusions
EES have shown lower device-related adverse events than BMS in patients with STEMI at 5 years of the stent implantation. However, event-free patients treated with EES presented with larger number of uncovered and malapposed struts and similar percentage of neoatherosclerosis than patients treated with BMS, as assessed by OCT, at 5 years. According to the OCT findings and the absence of adverse events in this selected group of patients, the amount of those OCT observations reported in the present study may have poor correlation with device-related clinical outcomes beyond 5 years. However, the clinical relevance of these findings warrants longer clinical follow-up.
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